← All organizations
AGO Germany
Academic/HospitalWebsite ↗
Also known as: AGO, ASCO, DKG | AGO Breast Study Group e.V. | AGO-OVAR, AGO Ovarian Cancer Study Group | AGO-OVAR, Ovarian Cancer Study Group, Germany; Ubbo-Emmius-Klinik gGmbH Aurich, Germany | AGO Research GmbH | AGO Study Group | AGO Study Group (Study Group of the Arbeitsgemeinschaft Gynaekologische Onkologie) | AGO-TraFo
Highest phase reached
Phase 4
First clinical trial
Sep 1, 1999Last known activity
Jan 1, 2024
Timeline
1990s
- Jan 1, 1993
AGO Germany— Founded
Drugs by trial phase (40 distinct, 37 trials)
Phase 4 (8 own, 0 via acquisition)
Phase 3 (19 own, 0 via acquisition)
Indications
Studied for
- Anemia
- Breast Neoplasms
- Carcinoma
- Carcinoma, Ductal, Breast
- Carcinoma, Ovarian Epithelial
- Carcinosarcoma
- Endometrial Neoplasms
- Fallopian Tube Neoplasms
- Genital Diseases, Female
- Genital Neoplasms, Female
- Hypersensitivity
- Inflammatory Breast Neoplasms
- Leiomyosarcoma
- Mixed Tumor, Mullerian
- Neoplasms
- Ovarian Diseases
- Ovarian Neoplasms
- Peritoneal Neoplasms
- Recurrence
- Sarcoma
- Uterine Cervical Neoplasms
- Uterine Neoplasms
Recent trials (49)
- NCT05903833Lead sponsorPhase 2Jan 1, 2024
- NCT05452213CollaboratorPhase 4Aug 31, 2022
- NCT05126342Lead sponsorPhase 2May 1, 2022
- NCT05009082Lead sponsorPhase 3Mar 31, 2022
- NCT04644289Lead sponsorPhase 2Jul 31, 2021
- NCT04274426Lead sponsorPhase 2Jul 31, 2020
- NCT04111978CollaboratorPhase 3Jan 1, 2020
- NCT03690739Lead sponsorPhase 3Aug 9, 2019
- NCT03353831Lead sponsorPhase 3Sep 11, 2018
- NCT03220178CollaboratorPhase 4Jun 20, 2017
- NCT01864746CollaboratorPhase 3Nov 1, 2013
- NCT01837251Study chairPhase 3May 1, 2013
- NCT01837251Lead sponsorPhase 3May 1, 2013
- NCT01583426Overall official - principal investigatorPhase 3Jul 1, 2012
- NCT01462890Lead sponsorPhase 3Nov 1, 2011
Details
- Founded
- Hamburg, DE Jan 1, 1993
- Last known activity
- Jan 1, 2024